ERBB2 and breast carcinoma: The effect of HER2Mab on MCF7-HER2 cell proliferation is in agreement with previous reports that rhuMab2C4 or pertuzumab potently inhibits proliferation of HER2 overexpressing breast cancer cell lines, such as BT474 and SKBR3 [39, 41].